OBJECTIVE： To observe therapeutic efficacy and safety of prucalopride in the treatment of chronic constipation （CC）. METHODS： Totally of 100 CC patients were selected from anorectal department of our hospital during Jun. 2016-Jan. 2017， and then divided into control group and observation group according to random number table， with 50 cases in each group. Control group was given Mosapride citrate tablets 5 mg +Lactulose oral solution 10 mL orally， 3 times a day. Observation group was given Prucalopride succinate tablets 2 mg orally， once a day. Both groups were treated for consecutive 4 weeks. Clinical efficacies of 2 groups were observed， and the levels of serum inflammatory factors （IL-6， TNF-α， IFN-γ） and colonic transit time （total colonic transit time， left colonic transit time， right colonic transit time， rectosigmoid colonic transit time） were observed before and after treatment. The occurrence of defecation disorders and ADR were recorded. RESULTS： None of patient in 2 groups was cured. Total response rate of observation group was 94.00％， which was significantly higher than 78.00％ of control group， with statistical significance （P＜0.05）. Before treatment， there was no statistical significance in the levels of serum inflammatory factors or colonic transit time （P＞0.05）. After treatment， the levels of IL-6 and IFN-γ in control group， the levels of IL-6， TNF-α and IFN-γ in observation group were decreased significantly， and the levels of IL-6， TNF-α and IFN-γ in observation group were significantly lower than those of control group； the colonic transit time in 2 groups was shortened significantly， and observation group was significantly shorter than control group， with statistical significance （P＜0.05）. After treatment， the incidence of defecation， incomplete emptying， sense of obstruction and sense of rectal tenesmus in observation group were significantly lower than control group， with statistical significance （P＜0.05）. There was no statistical significance in the incidence of sense of rectal tenesmus after treatment or ADR between 2 groups （P＞0.05）. CONCLUSIONS： Compared with traditional plan of mosapride combined with lactulose， prucalopride can more effectively reduce the levels of serum inflammatory factors， shorten colonic transit time， reduce the occurrence of defecation disorders as defecation and incomplete emptying， with equivalent safety.